Oruka Therapeutics (ORKA) filed a mixed shelf registration statement late Thursday with the US Securities and Exchange Commission for the sale of up to $1 billion of its securities from time to time.
The securities cover common stock, preferred stock, depository shares and warrants, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.